[1] MA MX, QIN N, MIN Q, et al.Research progress in anti-COVID-19 drugs[J]. Journal of Wuhan Institute of Technology(武汉工程大学学报), 2020, 42(3): 237-245. [2] ZUO SY.How to strengthen China's pharmacovigilance for SARS-CoV-2 vaccines in post-marketing phase[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(11): 766-772. [3] LIU PC, CHEN JM, YAO WB.Improving pharmacovigilance system in China amid the COVID-19 epidemic[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(7): 389-398. [4] JEAN SS, LEE PI, HSUEH PR.Treatment options for COVID-19: The reality and challenges[J]. J Microbiol Immunol Infect, 2020, 53(3): 436-443. [5] ZHANG JW, HU X, JIN PF.Feasibility of favipiravir in the treatment of the coronavirus disease 2019[J]. China pharmaceuticals(中国药业), 2020, 29(6): 20-24. [6] LIU SL, LIU W.An overview on therapeutic drugs of COVID-19 and its mechanism[J]. Prac J Med & Pharm(实用医药杂志), 2021, 38(2): 180-183. [7] LAI S, MA JC, YANG ZM, et al.The potential and clinical application of favipiravir for the treatment of COVID-19[J]. Pharmacy Today(今日药学), 2020, 30(6): 372-376. [8] FURUTA Y, GOWEN BB, Takahashi K, et al.Favipiravir (T-705), a novel viral RNA polymerase inhibitor[J]. Antiviral Research, 2013, 100(2): 446-454. [9] HONG XB, YANG CE, DU JH, et al.Application evaluation and pharmaceutical care of favipiravir in COVID-19[J]. Pharmacy Today(今日药学), 2020, 30(12): 837-844. [10] ZHANG PM, LIU L, LEI YL.Research progress of antiviral drug favipiravir from the perspective of patent[J]. China Invention & Patent(中国发明与专利), 2020, 17(5): 50-57. [11] CAI QX, YANG MH, LIU DJ, et al.Experimental treatment with favipiravir for COVID-19: an open-label control study[J]. Engineering, 2020, 6(10): 1192-1198. [12] LIU B, REN LP, ZHANG T, et al.Verification of national reference standard of N-glycyl-L-tyrosine[J]. Chin Pharm J(中国药学杂志), 2020, 55(22): 1890-1894. [13] Pharmacopoeia Committee of Ministry of Health of People's Republic of China. Pharmacopoeia of the People's Republic of China, Part 4 (中华人民共和国药典,四部)[S]. Beijing: China Medical Science and Technology Press, 2020: 114-115. [14] XIONG J, LIU Y, NING BM, et al.Study on stability of methylparaben and sodium methyl parahydroxybenzoate reference standards[J]. Drug Evaluation Research(药物评价研究), 2020, 43(6): 1065-1070. [15] XIONG J, YANG HX, WU JM, et al.Moisture sorption properties research of chemical reference substances based on dynamic vapor sorption analysis technology[J]. Chin Pharm J(中国药学杂志), 2015, 50(6): 532-535. |